The Hematologist

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

Play

Open in

20 episodes
monthly
Avg 20 min
English

Episodes 20

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

#168
September 3 · 23 min
One on One With Mary Horowitz
In this episode contributing editor, Lori Muffly, MD, MS, speaks with a celebrated leader in the field of bone marrow transplantation, Mary Horowitz, MD, MS, of the Medical College of Wisconsin.
#167
July 21 · 21 min
A Secondary Consideration: How Real-World Evidence Can Inform Practice in the Management of Patients With Secondary CNS Lymphoma
In this episode, Contributing Editor, Brian Hill, MD, speaks with Juan Alderuccio, MD, of the University of Miami Cancer Center, about a landmark study that supports refined treatment approaches for secondary central nervous system large B-cell lymphoma.
#166
June 16 · 21 min
Targeting the Lectin Pathway in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
In this episode, Contributing Editor Meera Sridharan, MD, PhD, speaks with Hiroyuki Matsui, MD, PhD, assistant professor in the department of hematology at Kyoto University Hospital in Japan. Their conversation focuses on the role of narsoplimab in treating a potentially fatal hematologic disorder.
#165
May 8 · 17 min
Search for the Fountain of Youth: Can Bispecific Antibodies Resurrect Dysfunctional T Cells to Improve Outcomes in Richter Transformation?
In this episode, Contributing Editor Tycel Phillips, MD, speaks with Arnon Kater, MD, of Amsterdam University Medical Center in the Netherlands. Their conversation focuses on the potential role of bispecific antibodies in managing patients with Richter transformation.
#164
April 30 · 20 min
Not All Clots Are Created Equal: Refining Secondary Prevention of Venous Thromboembolism in Higher-Risk Patients
In this episode, Michael Scott, MD, from the University of Toronto, St. Michael’s Hospital, speaks with Samuel Wilson, MD, of the University of North Carolina at Chapel Hill. Their conversation focuses on recent trials examining secondary prevention of venous thromboembolism in higher-risk patients.
#163
April 9 · 21 min
Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia
In this episode, Contributing Editor Brian Hill, MD, PhD, speaks with Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center in New York. Their conversation focuses on Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia.
#162
March 9 · 22 min
VERONA and the Future of High-Risk Myelodysplastic Syndromes: A Conversation With Dr. Jacqueline Garcia
In this episode, Contributing Editor Charlotte Brierley, MD, PhD, speaks with Jacqueline Garcia, MD, assistant professor at the Dana Farber Cancer Institute and Harvard Medical School and an expert in myeloid neoplasms. Their discussion focuses on the VERONA trial and its impact on the myelodysplastic syndromes community.
#161
February 5 · 22 min
Leading With Lived Experience: Dr. Brian Koffman, Patient and CEO of the CLL Society
In this episode Contributing Editor Brian Hill, MD, talks with Brian Koffman, MDCM, retired family doctor and chronic lymphocytic leukemia patient. Dr. Koffman is co-founder and chief medical officer of the CLL Society. They discuss Dr. Koffman’s journey as both a physician and a patient.
#160
Oct 22, 2025 · 22 min
An Homage to the Treg Graft in Allogeneic Transplantation
In this episode, Shaji Kumar, MD, editor-in-chief of The Hematologist, and consultant in hematology at Mayo Clinic in Rochester, Minnesota, talks with Robert Negrin, MD, professor of medicine at Stanford University and president-elect of ASH. They discuss recent developments in reducing graft versus host disease in allogenic stem cell transplant.
#159
Sep 11, 2025 · 20 min
Less Is More: Low-Dose Direct Oral Anticoagulants for Extended Venous Thromboembolism Prophylaxis in Higher-Risk Patients
In this episode, Contributing Editor Samuel Wilson, MD, talks with Francis Couturaud, MD, PhD, Professor of Pulmonology at University of Brest in France. They discuss low-dose direct oral anticoagulants for extended venous thromboembolism prophylaxis.
#158
Aug 17, 2025 · 21 min
GATA Lot to Learn: Decoding the Drivers of Down Syndrome-Associated Acute Leukemias
In this episode, Contributing Editor, Lauren Pommert, MD, MS, leads a conversation with Karen Rabin, MD, PhD, pediatric oncologist at the University of California, San Francisco, and Hans Hitzler, MD, with SickKids Children's Hospital in Toronto. They discuss advances in understanding the disease biology of down syndrome associated acute leukemia. Support for this episode provided by Autolus.
#157
Jul 28, 2025 · 22 min
More Than Medicine: Peer Connection as a Therapeutic Adjunct in Acute Leukemia
In this episode, Contributing Editor Lori Muffly, MD, MS, leads a conversation with two patients — Matt and Rohan — both of whom have undergone cord blood transplants for their acute myeloid leukemia. They discuss the value of peer connection as a vital component of their leukemia and transplant journey.
#156
Jun 23, 2025 · 22 min
Pomalidomide: A Step on the PATH Forward for Treatment of Hereditary Hemorrhagic Telangiectasia
In this episode, Contributing Editor Surbhi Shah, MBBS, MD, a clinician, researcher, and educator at Mayo Clinic in Phoenix, Arizona, talks with Keith McCrae, MD, director of classical hematology at the Taussig Cancer Institute and professor of molecular medicine at the Cleveland Clinic Lerner College of Medicine in Ohio. They discuss a recent paper co-authored by Dr. McCrae, “Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.” Support for this episode provided by Autolus.
#155
May 24, 2025 · 18 min
Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston. They discuss a phase I study with recent results that point to a potentially significant advance in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
#154
May 16, 2025 · 10 min
When to STOP Treatment for Immune Thrombocytopenia in Patients Experiencing a Complete Response on Thrombopoietin Receptor Agonists
In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-term follow-up of the STOPAGO study, which focuses on the use of thrombopoietin receptor agonists on patients with immune thrombocytopenia. Support for this episode provided by Autolus.
#153
Apr 28, 2025 · 21 min
No Scientific Link Found Between Sickle Cell Trait and Sudden Death
In this episode, Contributing Editor Samuel Wilson, MD, MSCR, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Excellence. They talk about a systematic literature review, led by Dr. DeBaun and published in the journal Blood, that found no link between sickle cell trait and sudden death – a finding that challenges a long-standing myth about the trait. Support for this episode provide by Siemens Healthineers.
#152
Mar 31, 2025 · 20 min
Does This Star ‘GLO’? Taking Aim at Second-Line Diffuse Large B-Cell Lymphoma With Glofitamab Plus Gemcitabine and Oxaliplatin
In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School. They talk about the use of Glofit-GemOx in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Support for this episode provided by Autolus.
#151
Feb 27, 2025 · 26 min
The Rise of the HLA-Mismatched Unrelated Donor Transplant in the U.S.
In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine at Stanford University where she focuses on cellular therapy for adults with acute leukemia, talks with Steven Devine, MD, the chief medical officer at the National Marrow Donor Program. They talk about the rise of HLA-mismatched unrelated donor transplants in the U.S.
#150
Jan 31, 2025 · 23 min
The End of Transplant for Mantle Cell Lymphoma
In this episode, Contributing Editor Brian Hill, MD, PhD, director of the lymphoid malignancies program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, talks with Tim Fenske, MD, who at the time of this recording was joining the transplant and cell therapy group at Sarah Cannon Methodist Healthcare in San Antonio, Texas. Dr. Fenske previously led the lymphoma program at the Medical College of Wisconsin. They talk about a new study that found a lack of benefit in autologous stem cell transplantation for patients with mantle cell lymphoma.
#149
Dec 21, 2024 · 18 min
DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma
In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Meletios Dimopoulos, MD, a professor and chair of the Department of Clinical Therapeutics at the National and Kopodistrian University of Athens School of Medicine in Athens, Greece. They talk about a recent paper co-authored by Dr. Dimopoulos: “Belantamab Mafodotin, Pomalidomide (PA), and Dexamethasone in Multiple Myeloma.”

Showing 1–20 of 20 episodes